Alnylam Pharmaceuticals
ALNY
#618
Rank
โ‚น2.608 T
Marketcap
โ‚น20,152
Share price
-10.08%
Change (1 day)
57.20%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น351.33. In 2022 the company made an earnings per share (EPS) of -โ‚น794.13 a decrease over its 2021 EPS that were of -โ‚น615.47.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-57.54%
2022-โ‚น794.1329.03%
2021-โ‚น615.47-3.36%
2020-โ‚น636.84-8.48%
2019-โ‚น695.827.67%
2018-โ‚น646.2439.74%
2017-โ‚น462.4612.94%
2016-โ‚น409.4638.84%
2015-โ‚น294.91-32.88%
2014-โ‚น439.38259.44%
2013-โ‚น122.24-31.25%
2012-โ‚น177.8052.94%
2011-โ‚น116.2630.77%
2010-โ‚น88.90-8.77%
2009-โ‚น97.4578.13%
2008-โ‚น54.71-70.78%
2007-โ‚น187.2199.09%
2006-โ‚น94.03-43.88%
2005-โ‚น167.54-82.33%
2004-โ‚น948.29-59.23%
2003-โ‚น2,326

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น145.32-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,194-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น669.32 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.08-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น144.46-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น319.70-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น271.85-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น170.96-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel